Joseph Hargett

Joseph Hargett

Despite hailing from the Greater Cincinnati, Ohio area, Joseph Hargett has spent nearly the past decade elbow-deep in Wall Street.  Specializing in financial writing, options strategies and stock-market analysis, Joseph cut his teeth in the research department of Cincinnati-based Schaeffer’s Investment Research.

While at Schaeffer’s, Joseph wrote market, stock and options commentary for SchaeffersResearch.com, and was lead editor for The Options Advisor (the nation’s leading options newsletter).

Joseph has since moved on to become a prolific Forbes contributor in the options realm, as well as a lead copy editor and contributor for a well respected investment newsletter publisher.  Joseph’s commentary has appeared in a plethora of media outlets, including The Wall Street JournalThe New York TimesMoney Show Digest, Reuters, CBE MarketWatch and Sentiment Magazine.

Recent Articles

Can Ambarella Inc (AMBA) Move Out of GoPro Inc’s Shadow?

With GoPro problems already priced in, AMBA stock looks ready to rally as Ambarella broadens its revenue base.

Wednesday’s Vital Data: Apple Inc. (AAPL), Michael Kors Holdings Ltd (KORS) and Micron Technology, Inc. (MU)

Apple (AAPL) is plagued by rumors of a longer iPhone refresh cycle, Michael Kors (KORS) blows out earnings and Micron (MU) options rise on analyst upgrades.

Tuesday’s Vital Data: Alibaba Group Holding Ltd (BABA), Bank of America Corp (BAC) and Tesla Motors Inc (TSLA)

Alibaba (BABA) was bolstered by bullish comments, BofA (BAC) options are up on technicals and Tesla (TSLA) sets a date for its gigafactory.

Friday’s Vital Data: Netflix, Inc. (NFLX), Apple Inc. (AAPL) and Tesla Motors Inc (TSLA)

Netflix (NFLX) call options rally on Apple (AAPL) acquisition speculation while Tesla Motors (TSLA) breakout drives technical buying activity.

Thursday’s Vital Data: Alibaba Group Holding Ltd (BABA), Yahoo! Inc. (YHOO) and Sarepta Therapeutics Inc (SRPT)

Alibaba (BABA) put options pile on SEC investigation, Yahoo! (YHOO) calls soar on AT&T (T) bid and Sarepta (SRPT) spikes on FDA delay.